Success Metrics

Clinical Success Rate
79.3%

Based on 69 completed trials

Completion Rate
79%(69/87)
Active Trials
41(27%)
Results Posted
84%(58 trials)
Terminated
18(12%)

Phase Distribution

Ph phase_3
14
9%
Ph not_applicable
3
2%
Ph phase_2
81
53%
Ph phase_4
4
3%
Ph early_phase_1
1
1%
Ph phase_1
46
30%

Phase Distribution

47

Early Stage

81

Mid Stage

18

Late Stage

Phase Distribution149 total trials
Early Phase 1First-in-human
1(0.7%)
Phase 1Safety & dosage
46(30.9%)
Phase 2Efficacy & side effects
81(54.4%)
Phase 3Large-scale testing
14(9.4%)
Phase 4Post-market surveillance
4(2.7%)
N/ANon-phased studies
3(2.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

69.0%

69 of 100 finished

Non-Completion Rate

31.0%

31 ended early

Currently Active

41

trials recruiting

Total Trials

152

all time

Status Distribution
Active(41)
Completed(69)
Terminated(31)
Other(11)

Detailed Status

Completed69
Recruiting22
Active, not recruiting19
Terminated18
Withdrawn13
unknown10

Development Timeline

Analytics

Development Status

Total Trials
152
Active
41
Success Rate
79.3%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (0.7%)
Phase 146 (30.9%)
Phase 281 (54.4%)
Phase 314 (9.4%)
Phase 44 (2.7%)
N/A3 (2.0%)

Trials by Status

completed6945%
unknown107%
active_not_recruiting1913%
terminated1812%
suspended11%
recruiting2214%
withdrawn139%

Recent Activity

41 active trials
Showing 5 of 152
active_not_recruitingphase_2

Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma

NCT01920932
recruitingphase_3

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

NCT05675410
completedphase_1

Brentuximab Vedotin for Systemic Sclerosis

NCT03222492
active_not_recruitingphase_3

Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma

NCT02166463
active_not_recruitingphase_3

Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

NCT03907488
View all 152 trials

Clinical Trials (152)

Showing 20 of 152 trialsScroll for more
NCT01920932Phase 2

Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma

Active Not Recruiting
NCT05675410Phase 3

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

Recruiting
NCT03222492Phase 1

Brentuximab Vedotin for Systemic Sclerosis

Completed
NCT02166463Phase 3

Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma

Active Not Recruiting
NCT03907488Phase 3

Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

Active Not Recruiting
NCT03057795Phase 2

Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin Lymphoma

Active Not Recruiting
NCT01896999Phase 1

Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Active Not Recruiting
NCT03755804Phase 2

Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17

Active Not Recruiting
NCT07275216Phase 2

Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard Treatment

Recruiting
NCT06377566Phase 2

A Study of BV-AVD in People With Bulky Hodgkin Lymphoma

Recruiting
NCT04404283Phase 3

Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

Active Not Recruiting
NCT05922904Phase 2

PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma

Active Not Recruiting
NCT05481437

A Survey of Brentuximab Vedotin in Pediatric Participants With Hodgkin Lymphoma

Recruiting
NCT05414500Phase 1

Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides

Recruiting
NCT04685616Phase 3

Brentuximab Vedotin in Early Stage Hodgkin Lymphoma

Recruiting
NCT04609566Phase 2

Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors

Completed
NCT03652441Phase 2

Consolidation Therapy With Brentuximab Vedotin After Allogeneic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma

Completed
NCT01712490Phase 3

A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma

Completed
NCT06831370Phase 4

A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India

Recruiting
NCT04745949Phase 2

PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapy

Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
152